In this paper, the compound ethyl 2-(5-methyl-1,2,4-triazolo[1,5-a]pyrimidin-7-yl)pent-4-enoate was synthesized and identified by FT-IR, H-1 and C-13 NMR, UV-Vis. And single crystal x-ray diffraction. In addition, theoretical calculations including an optimized structure analysis, Hirshfeld surface analysis, High Occupied Molecular Orbital (HOMO)-Lowest Unoccupied Molecular Orbital (LUMO) analysis, UV -Vis. parameters with an IEFPCM solvent model, MEP-Molecular Electrostatic Potential and NLO-NonLinear Optical properties and a molecular docking analysis were carried out. All theoretical computations were performed by the DET/B3LYP functional and the 6-311++G(d,p) basis set in the ground state. The assignments of calculated infrared vibrational frequencies were performed using the VEDA4 software for the first time through the optimized structure's chk*. and the experimental and theoretical data are in good agreement. In addition, molecular docking studies between ethyl 2-(5-methyl-1,2,4-triazolo [1,5-a]pyrimidin-7-yl)pent-4-enoateand the c-MET protein (PDB ID: 5EOB) were performed by using the AutoDock Vina program. The title molecule appears to be a good inhibitor for cancer treatment due to its binding energy and ability to adhere to the active sites of the protein. (C) 2020 Elsevier B.V. All rights reserved.